Tiotropium/Salmeterol Inhalation Powder in COPD
Public ClinicalTrials.gov record NCT00668772. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 24-week (+ 24 Week Extension) Placebo-controlled (Only 1st 12-week Period), Double-Blind, Parallel-group, Efficacy and Safety Comparison of Fixed-dose Combination (FDC) Tiotropium/Salmeterol, Tiotropium, Salmeterol and FDC Tiotropium/Salmeterol Plus Salmeterol in Chronic Obstructive Pulmonary Disease (COPD) Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index (BDI)/Transition Dyspnoea Index (TDI), the effect on health status as determined by the St George Respiratory Questionnaire (SGRQ) and the effect on chronic obstructive pulmonary disease (COPD) exacerbations
Study identification
- NCT ID
- NCT00668772
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 207 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2008
- Primary completion
- Nov 20, 2008
- Completion
- Nov 20, 2008
- Last update posted
- Jul 15, 2026
2008
United States locations
- U.S. sites
- 16
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1184.15.01069 Boehringer Ingelheim Investigational Site | Anniston | Alabama | — | — |
| 1184.15.01071 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 1184.15.01054 Boehringer Ingelheim Investigational Site | Clearwater | Florida | — | — |
| 1184.15.01063 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1184.15.01064 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 1184.15.01065 Boehringer Ingelheim Investigational Site | Savannah | Georgia | — | — |
| 1184.15.01052 Boehringer Ingelheim Investigational Site | New Orleans | Louisiana | — | — |
| 1184.15.01055 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1184.15.01058 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1184.15.01062 Boehringer Ingelheim Investigational Site | St Louis | Missouri | — | — |
| 1184.15.01072 Boehringer Ingelheim Investigational Site | Summit | New Jersey | — | — |
| 1184.15.01053 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | — | — |
| 1184.15.01070 Boehringer Ingelheim Investigational Site | New York | New York | — | — |
| 1184.15.01057 Boehringer Ingelheim Investigational Site | Elizabeth City | North Carolina | — | — |
| 1184.15.01059 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1184.15.01051 Boehringer Ingelheim Investigational Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 48 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00668772, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 15, 2026 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00668772 live on ClinicalTrials.gov.